Quantcast
Channel: BioTuesdays » GILD
Browsing all 3 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

Gilead Sciences to acquire YM BioSciences

Gilead Sciences (NASDAQ:GILD) and has agreed to acquire YM BioSciences (NYSE MKT:YMI, TSX:YM) for $2.95 a share. The transaction has received the unanimous approval of YM’s board and values YM at about...

View Article



Image may be NSFW.
Clik here to view.

Galectin targets silent epidemic in liver fibrosis

Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). Dr. Peter...

View Article

Image may be NSFW.
Clik here to view.

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...

View Article
Browsing all 3 articles
Browse latest View live




Latest Images